GSK plc (GSK) 주가 예측

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).